Prevalence of Antinuclear Antibodies in Schoolchildren During Puberty and Possible Relationship with Musculoskeletal Pain: A Longitudinal Study

Francesca Sperotto, Giorgio Cuffaro, Sara Brachi, Mara Seguso, and Francesco Zulian

ABSTRACT. Objective. The role of antinuclear antibodies (ANA) in children has still to be elucidated. The aim of our study was to evaluate the prevalence and persistence of ANA in schoolchildren during the puberty switch, and the possible relationship with chronic noninflammatory musculoskeletal pain (MSP).

Methods. Children aged 8–13 years and attending 4 public schools underwent a clinical examination, focusing on pubertal stage and presence of chronic noninflammatory MSP. Laboratory tests to determine the autoantibody-profile were also performed. Subjects with ANA positivity (titer ≥ 1:80) and/or chronic noninflammatory MSP were re-evaluated 3 years later.

Results. Two hundred sixty-one subjects enrolled in the study and 12.3% were ANA-positive, equally distributed in terms of sex and pubertal status. Three years later, in the group of patients studied for chronic noninflammatory MSP (n = 67), ANA positivity significantly increased from 13.4% to 44.8%. In the ANA-positive cohort at baseline (n = 28), 92.9% of subjects were confirmed as being ANA-positive with a significantly increased titer. No association between ANA positivity and chronic noninflammatory MSP was found.

Conclusion. ANA prevalence and titers increase during puberty, especially in females, but have no relationship with chronic noninflammatory MSP. This finding may be related to the complex hormonal changes during the puberty switch period and opens new insights into autoimmunity.

Key Indexing Terms:
ANTINUCLEAR ANTIBODIES  PUBERTY  MUSCULOSKELETAL PAIN

Antinuclear antibodies (ANA) are frequently found in pediatric patients with connective tissue diseases but may be triggered by infections, drugs, or a neoplastic process\textsuperscript{1,2} and have even been found in healthy individuals\textsuperscript{3,4,5,6}. One study previously reported ANA positivity in association with noninflammatory musculoskeletal pain (MSP) in early childhood, but found no clinical relevance\textsuperscript{7}.

The prevalence of positive ANA, reported in the literature for healthy individuals, ranges from 13.3%, if we consider a titer ≥ 1:80, to 5.0% with a titer ≥ 1:160\textsuperscript{3,4,7,8}. To date, few studies have addressed the role of ANA in healthy subjects, but no one has explored their frequency and meaning across the puberty switch, a period in which many autoimmune and connective tissue diseases develop\textsuperscript{9}. The aim of our study was to evaluate the prevalence and persistence of ANA in subjects with no evident autoimmune disease and their possible relationship with chronic non-inflammatory MSP over the course of puberty.

MATERIALS AND METHODS
In June 2009, we conducted a study on subjects attending 3 primary and 1 secondary state schools in the District of Padua, Italy, in order to evaluate the prevalence of chronic noninflammatory MSP, the prevalence of auto-antibodies, and their reciprocal relationship.

Chronic MSP was defined as continuous or recurrent pain lasting more than 3 months and heavily interfering with daily activities, according to the International Association for the Study of Pain\textsuperscript{10}. Each subject underwent a careful, general, and rheumatologic examination including the evaluation of the pubertal stage and the family history for autoimmune diseases in first degree relatives. The pubertal stage was assessed by the presence of secondary signs of pubertal development. For females, puberty was defined by breast development with a Tanner stage ≥ 3 and menarche. For males, puberty was defined by testicles volume ≥ 12 ml and evident pubic and underarm hair\textsuperscript{11,12}.

Individuals with a history or the presence of neurologic, skeletal, metabolic, or autoimmune diseases were excluded to avoid a selection bias. Laboratory tests to determine the presence of ANA, extractable nuclear antigen antibodies (ENA), and anti-dsDNA were also performed. The ANA test consisted of the gold standard immunofluorescence antinuclear antibody test on HEp-2 cells (INOVA), using a fluorescein-conjugated anti-human immunoglobulin G (IgG) as a secondary antibody, according to the most recent position statement\textsuperscript{13,14}. Samples were processed sequentially using a Zenit-plus analyzer and read by a NIKON fluorescence microscope and an LED-microscope by 2 independent operators. We considered positive a sample with titer ≥ 1:80. To increase sensitivity, sera
were also analyzed on triple murine tissue (kidney, stomach, liver; INOVA). The presence of ENA (SSA, SSB, Sm, RNP, Jo-1, Scl-70) was detected using the fluoride-immune-enzymatic method (PHADIA). Samples > 0.7 were considered positive\(^\text{13}\). Anti-dsDNA was determined on a *Crickheda luciliae* substrate (INOVA)\(^\text{11}\).

Subjects with ANA positivity and/or chronic noninflammatory MSP were evaluated with the same methods 3 years later. Again, individuals with a history or the presence of neurologic, skeletal, metabolic, or autoimmune diseases were excluded, to avoid a further selection bias.

Demographic, clinical, and laboratory characteristics of patients were analyzed using descriptive statistics. Pearson’s chi-square and Fisher’s exact test were used to compare categorical variables between subgroups. Clinical variables obtained at baseline (2009) and 3 years later (2012) were compared using the Wilcoxon test and the McNemar test. A value of \(p < 0.05\) was considered significant. The analysis was performed using StatsDirect statistical software (version 2.7.8, StatsDirect Ltd.).

The study was approved by the ethics committee of the Padua District Health Authority.

**RESULTS**

At baseline, blood tests were performed on 261/289 (90.3%) subjects, aged 8–13 years old, with an F:M ratio of 1:1; 70.5% were prepubertal and 29.5% pubertal (Table 1). Thirty-two subjects (12.3%) had ANA+ results, with the following distribution: 8.4% had 1:80 titer, 3.8% \(\geq 1:160\), and 0.8% \(\geq 1:320\) (Table 1). ANA positivity was equally distributed in terms of sex and pubertal status. None of the subjects that were ANA+ resulted in positive ENA or anti-dsDNA testing. A positive family history for autoimmune conditions in first-degree relatives was reported in 6.5% of the subjects, but no significant relationship with ANA positivity was found.

Three years later, in 2012, we re-evaluated the subjects with either chronic noninflammatory MSP at baseline (\(n = 67\)) and/or ANA+ at baseline (\(n = 28\)). At followup, 7 patients overlapped between these 2 cohorts (Table 1).

ANA positivity, in the group of patients with previous chronic noninflammatory MSP, increased from 13.4% (9/67) to 44.8% (30/67; \(p < 0.001\)), while no significant changes in the prevalence of positive family history for autoimmune diseases were found. Thirty-seven subjects (55.2%) were persistently symptomatic, but there was no significant association with ANA. ANA positivity showed a trend that involved more prepubertal subjects (59.1%) than pubertal ones (37.8%) and more females (53.6%) than males (38.5%), but this was not statistically significant. In particular, ANA positivity involved more pubertal females than pubertal males (50.0% vs 28.0%), while in the prepubertal period the prevalence was nearly equal between sexes.

The cohort of subjects previously ANA+ included 28 subjects whose demographic characteristics are summarized in Table 1. The vast majority (92.9%) of subjects with ANA+ at baseline were still positive at the 3-year followup evaluation. Two subjects decreased their titer from 1:80 to 1:40, but none became negative. ANA titer had the following distribution: 17.9% had 1:80 titer, 75.0% \(\geq 1:160\), 50.0% \(\geq 1:320\), and 14.3% \(\geq 1:640\). Overall, autoantibodies titer showed a significant increase over time (\(p = 0.002\)), while the prevalence of positive family history for autoimmune diseases did not significantly change during the

---

**Table 1.** Demographic and clinical characteristics of schoolchildren according to the presence of antinuclear antibodies (ANA) or musculoskeletal pain (MSP).

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Initial Cohort, n (%)</th>
<th>Subjects with MSP at Baseline, n (%)</th>
<th>Subjects ANA+ at Baseline, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>In 2009, n = 261</td>
<td>In 2009, n = 77</td>
<td>In 2012, n = 67</td>
</tr>
<tr>
<td>Lost to followup</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female:male</td>
<td>1:1</td>
<td>1:1.5</td>
<td>1:1.4</td>
</tr>
<tr>
<td>Mean age, yrs (range)</td>
<td>10.6 (8–13)</td>
<td>10.8 (8–13)</td>
<td>14 (11–16)</td>
</tr>
<tr>
<td>MS</td>
<td>77 (29.5)</td>
<td>77 (100.0)</td>
<td>37 (55.2)</td>
</tr>
<tr>
<td>ANA+</td>
<td>32 (12.3)</td>
<td>10 (13.0)</td>
<td>30 (44.8)</td>
</tr>
<tr>
<td>Titer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:80</td>
<td>22 (8.4)</td>
<td>6 (7.8)</td>
<td>17 (25.4)</td>
</tr>
<tr>
<td>1:160</td>
<td>8 (3.1)</td>
<td>3 (3.9)</td>
<td>6 (8.9)</td>
</tr>
<tr>
<td>1:320</td>
<td>1 (0.4)</td>
<td>0 (0.0)</td>
<td>4 (5.9)</td>
</tr>
<tr>
<td>1:640</td>
<td>1 (0.4)</td>
<td>1 (1.3)</td>
<td>3 (4.5)</td>
</tr>
<tr>
<td>Pattern</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nuclear fine speckles</td>
<td>12 (37.5)</td>
<td>4 (40.0)</td>
<td>23 (76.7)</td>
</tr>
<tr>
<td>Homogeneous</td>
<td>10 (31.3)</td>
<td>2 (20.0)</td>
<td>5 (16.7)</td>
</tr>
<tr>
<td>Nuclear coarse speckles</td>
<td>5 (15.6)</td>
<td>2 (20.0)</td>
<td>2 (6.6)</td>
</tr>
<tr>
<td>Nucleolar</td>
<td>3 (9.4)</td>
<td>1 (10.0)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Centriolar</td>
<td>1 (3.1)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Multiple nuclear dots</td>
<td>1 (3.1)</td>
<td>1 (10.0)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Prepubertal subjects</td>
<td>184 (70.5)</td>
<td>64 (83.1)</td>
<td>22 (32.8)</td>
</tr>
<tr>
<td>Pubertal subjects</td>
<td>77 (29.5)</td>
<td>13 (16.9)</td>
<td>45 (67.2)</td>
</tr>
<tr>
<td>Family history of autoimmune diseases</td>
<td>17 (6.5)</td>
<td>4 (5.2)</td>
<td>5 (7.1)</td>
</tr>
</tbody>
</table>

---

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2014. All rights reserved.
study period (Table 1). Eleven subjects (39.3%) suffered from chronic noninflammatory MSP, but no significant association between ANA-positivity and symptoms was found.

The most frequent ANA-pattern found both at baseline and at followup was the “fine-speckled” as shown in Table 1.

DISCUSSION
It is well known that ANA frequently arise in the sera of children with autoimmune and connective tissue disease, including systemic lupus erythematosus, scleroderma, and juvenile idiopathic arthritis, but it is also present in organ-specific autoimmune diseases, such as autoimmune hepatitis and thyroiditis or during infectious processes, drug treatments or rarely, with malignancy. ANA can also be found in healthy individuals, without any significant difference in prevalence for sex or age. The prevalence of ANA reported in the general population ranges from 13.3% for a titer ≥ 1:80, to 3.3% for a titer ≥ 1:320. Studies in children reported similar or lesser prevalence. The prevalence and titer of ANA increase across puberty, because no significant statistical association was found.

Although very few studies have addressed the issue of the role of ANA in healthy subjects, none has explored its frequency and meaning and across the puberty switch, a period in which onset occurs for many autoimmune and connective tissue diseases. The cohort of children with chronic noninflammatory MSP at baseline showed an increased frequency of ANA positivity across puberty (from 13.4% to 44.8%). This increased frequency was independent from the persistence of symptoms and confirmed the results of a previous study showing the absence of a significant association between ANA positivity and noninflammatory MSP. On the other hand, a positive family history for autoimmune diseases does not seem to influence the prevalence of ANA during this period, because no significant statistical association was found.

As for the ANA pattern, fine speckled was the one most frequently found (Table 1). Although we have no precise definition on the subset of nuclear fine speckled pattern, several of the cases may correspond to the dense fine speckled pattern, which has been shown to consistently occur more frequently in healthy subjects rather than in those with autoimmune diseases.

We do not have a clear explanation of why ANA positivity increases both in prevalence and titer across puberty. Clinical and experimental evidence supports the hypothesis that sex hormones modulate immunity. In fact, the majority of autoimmune diseases are more common in females than in males and, when stratified by age, their onset is more frequently around puberty. Females tend to mount stronger reactions against infection than males and this is due to different factors such as genetics and imprinting elements, hormonal patterns, and cytokine profiles. In particular, the cytokines balance is responsible for determining the quality and direction of the immune response and females tend to show instability of this balance with predominantly proinflammatory TH1-mediated reactions as compared with males. Our findings seem to be consistent with this evidence, because ANA were found more frequently in pubertal females than in males.

The hypothalamic-pituitary axis, whose activity starts around 4 years before puberty, also plays an important role in modulating the immune system. Adenohypophysal hormones seem to increase the differentiation and proliferation of T cells, making them more susceptible to antigenic stimulation. The preadolescence period, in predisposed subjects, might stimulate an unspecific immune response resulting in ANA production.

The prevalence and titer of ANA increase across puberty, especially in females, but have no relationship with chronic noninflammatory MSP. None of the ANA-positive subjects developed rheumatic or autoimmune conditions over time. Further longterm prospective studies are needed to clarify the potential role of ANA as a marker of autoimmune-rheumatic conditions, particularly in the puberty switch period.

REFERENCES


